Fig. 2: The immunotherapy group has a higher risk of developing subsequent irAEs across all cancer types under study. | npj Precision Oncology

Fig. 2: The immunotherapy group has a higher risk of developing subsequent irAEs across all cancer types under study.

From: Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types

Fig. 2

A Melanoma. B Renal cancer. C Head and neck cancer. D Squamous cell carcinoma. E Basal cell carcinoma. F Brain cancer. G Lung cancer. The point estimates of the hazard ratios comparing the immunotherapy group with either chemotherapy (red curves) or targeted therapy (cyan curves) in 3, 6, 9, 12, and 15 months after treatment initiation are shown. Their corresponding 95% confidence intervals are displayed by the shaded areas. Chemotherapy agents include carboplatin, cisplatin, doxorubicin, fluorouracil, gemcitabine, and paclitaxel. Targeted therapy agents include bevacizumab, temsirolimus, axitinib, cabozantinib, erlotinib, everolimus, pazopanib, sorafenib, and sunitinib. The detailed list of CPT/HCPCS procedure codes and national drug codes can be found in Tables S3–S6. The number on the top right indicates the number of matched patients in the treatment group. With the exception of renal cancer, the hazard ratios did not differ significantly when using the chemotherapy group or the targeted therapy group as the comparison group. With the exception of comparing immunotherapy with targeted therapy among patients with squamous cell carcinoma of the skin and brain cancer, the 95% confidence intervals in all other comparisons involving all immunotherapy drugs do not include 1.

Back to article page